J Dig Cancer Res.  2025 Aug;13(2):107-111. 10.52927/jdcr.2025.13.2.107.

Recent Advances in Noninvasive Tests for Colorectal Cancer Screening

• Soh JS

• KMID: 2571545
• DOI: http://doi.org/10.52927/jdcr.2025.13.2.107

Abstract

Colorectal cancer (CRC) is the third most common cancer worldwide and the second leading cause of cancer-related mortality. Colonoscopy is the gold standard for CRC screening; however, its invasive nature, high cost, and requirements of bowel preparation limit participation. Alternative methods such as fecal immunochemical tests (FIT), CT colonoscopy, stool DNA tests, and blood-based tests, are gaining attention because of their noninvasive nature. FIT has demonstrated moderate sensitivity but limited accuracy for screening precancerous lesions. CT colonography requires bowel preparation and involves exposure to radiation. Stool DNA tests which include the next-generation multitarget and Syndecan-2 methylation tests, offer higher sensitivity for CRC detection. Blood-based tests are more convenient compared to stool-based screening, and recently the circulating tumor cell DNA test approved by the U.S. FDA has shown improved sensitivity. Novel stool-based RNA-FIT and cell-free blood-based DNA tests are also currently being developed. Expanding noninvasive screening options might enhance CRC detection rates and screening participation.

Keyword

Colorectal cancer; Screening; Noninvasive tests; Stool DNA test; Blood-based test

Reference

1. Jung KW, Kang MJ, Park EH, et al. 2024; Prediction of cancer incidence and mortality in Korea, 2024. Cancer Res Treat. 56:372–379. https://doi.org/10.4143/crt.2024.252. DOI: 10.4143/crt.2024.252. PMCID: PMC11016663.

2. Rim JH, Youk T, Kang JG, et al. 2017; Fecal occult blood test results of the national colorectal cancer screening program in South Korea (2006-2013). Sci Rep. 7:2804. https://doi.org/10.1038/s41598-017-03134-9. DOI: 10.1038/s41598-017-03134-9. PMID: 28584248. PMCID: PMC5459855.

3. Peterse EFP, Meester RGS, Siegel RL, et al. 2018; The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline. Cancer. 124:2964–2973. https://doi.org/10.1002/cncr.31543. DOI: 10.1002/cncr.31543. PMID: 29846933. PMCID: PMC6033623.

4. Exact Sciences. 2014. FDA approves Exact Sciences' Cologuard®; first and only stool DNA noninvasive colorectal cancer screening test. https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2014/FDA-Approves-Exact-Sciences-Cologuard-First-and-Only-Stool-DNA-Noninvasive-Colorectal-Cancer-Screening-Test/. accessed Mar 27, 2025.

5. Genomictree. 2018. Colorectal cancer detection product (tumor-related DNA test reagent). http://earlytect.com/products/earlytect-colon-cancer/. accessed Mar 27, 2025.

6. Imperiale TF, Gruber RN, Stump TE, Emmett TW, Monahan PO. 2019; Performance characteristics of fecal immunochemical tests for colorectal cancer and advanced adenomatous polyps: a systematic review and meta-analysis. Ann Intern Med. 170:319–329. https://doi.org/10.7326/m18-2390. DOI: 10.7326/M18-2390. PMID: 30802902.

7. Pokharel R, Lin YS, McFerran E, O'Mahony JF. 2023; A systematic review of cost-effectiveness analyses of colorectal cancer screening in Europe: have studies included optimal screening intensities? Appl Health Econ Health Policy. 21:701–717. https://doi.org/10.1007/s40258-023-00819-3. DOI: 10.1007/s40258-023-00819-3. PMID: 37380865. PMCID: PMC10403417.

8. Knudsen AB, Zauber AG, Rutter CM, et al. 2016; Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force. JAMA. 315:2595–2609. https://doi.org/10.1001/jama.2016.6828. DOI: 10.1001/jama.2016.6828. PMID: 27305518. PMCID: PMC5493310.

9. Pickhardt PJ, Hassan C, Halligan S, Marmo R. 2011; Colorectal cancer: CT colonography and colonoscopy for detection-systematic review and meta-analysis. Radiology. 259:393–405. https://doi.org/10.1148/radiol.11101887. DOI: 10.1148/radiol.11101887. PMID: 21415247. PMCID: PMC3079122.

10. IJspeert JE, Tutein Nolthenius CJ, Kuipers EJ, et al. 2016; CT-colonography vs. colonoscopy for detection of high-risk sessile serrated polyps. Am J Gastroenterol. 111:516–522. https://doi.org/10.1038/ajg.2016.58. DOI: 10.1038/ajg.2016.58. PMID: 27021193.

11. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. 2014; Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 370:1287–1297. https://doi.org/10.1056/nejmoa1311194. DOI: 10.1056/NEJMoa1311194. PMID: 24645800.

12. Imperiale TF, Porter K, Zella J, et al. 2024; ; BLUE-C Study Investigators. Next-generation multitarget stool DNA test for colorectal cancer screening. N Engl J Med. 390:984–993. https://doi.org/10.1056/nejmoa2310336. DOI: 10.1056/NEJMoa2310336. PMID: 38477986.

13. Han YD, Oh TJ, Chung TH, et al. 2019; Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA. Clin Epigenetics. 11:51. https://doi.org/10.1186/s13148-019-0642-0. DOI: 10.1186/s13148-019-0642-0. PMID: 30876480. PMCID: PMC6419806.

14. Church TR, Wandell M, Lofton-Day C, et al. 2014; ; PRESEPT Clinical Study Steering Committee, Investigators and Study Team. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 63:317–325. https://doi.org/10.1136/gutjnl-2012-304149. DOI: 10.1136/gutjnl-2012-304149. PMID: 23408352. PMCID: PMC3913123.

15. Chung DC, Gray DM 2nd, Singh H, et al. 2024; A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med. 390:973–983. https://doi.org/10.1056/nejmoa2304714. DOI: 10.1056/NEJMoa2304714. PMID: 38477985.

16. Barnell EK, Wurtzler EM, La Rocca J, et al. 2023; Multitarget stool RNA test for colorectal cancer screening. JAMA. 330:1760–1768. https://doi.org/10.1001/jama.2023.22231. DOI: 10.1001/jama.2023.22231. PMID: 37870871. PMCID: PMC10594178.

17. Ulz P, Perakis S, Zhou Q, et al. 2019; Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. Nat Commun. 10:4666. https://doi.org/10.1038/s41467-019-12714-4. DOI: 10.1038/s41467-019-12714-4. PMID: 31604930. PMCID: PMC6789008.